13F Holdings
中文EN

HEPA Hepion Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1583771 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.4%
TTM EPS YoY98.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-166.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets180.2%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-120.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$0$0$0
R&D expense$445,512$11.85M$35.64M$33.27M$20.40M
SG&A expense$3.32M$7.50M$9.62M$10.35M$10.01M
Operating income-$4.16M-$19.35M-$48.45M-$45.49M-$30.40M
Interest expense——$9,465$10,164$8,859
Pretax income-$8.28M-$16.16M-$49.34M-$45.08M-$32.72M
Income tax—-$2.97M-$409,022-$2.88M$0
Net income-$8.28M-$13.19M-$48.93M-$42.20M-$32.72M
EBITDA—-$19.32M-$48.38M-$45.41M-$30.32M
EPS (basic)-0.88-107.35-616.07-11.90-0.47
EPS (diluted)-0.88-107.35-616.07-11.90-0.47
Weighted avg. shares (diluted)9.41M122,89479,4163.81M70.29M
Balance sheet
Cash & equivalents$1.83M$406,408$14.79M$51.19M$91.35M
Current assets$3.07M$1.61M$17.49M$56.50M$97.45M
PP&E, net——$29,487$81,620$152,772
Goodwill———$0$1.87M
Total assets$3.07M$1.61M$18.09M$60.24M$103.55M
Current liabilities$299,383$3.14M$5.29M$7.89M$8.21M
Total liabilities$402,405$3.48M$10.81M$10.39M$10.56M
Shareholders' equity$2.67M-$1.86M$7.28M$49.86M$93.00M
Shares outstanding11.62M139,16896,3753.81M76.23M
Cash flow statement
Operating cash flow-$3.27M-$18.22M-$40.89M-$34.96M-$31.22M
Capital expenditure——$14,304$16,336$130,405
Free cash flow——-$40.90M-$34.98M-$31.35M
Investing cash flow-$132,117-$600,000-$14,304-$14,070-$130,405
Financing cash flow$4.83M$4.35M$4.49M-$5.14M$81.98M
Depreciation & amortization—$30,758$67,131$77,461$86,073
Stock-based compensation$20,783$791,645$1.34M$2.55M$4.67M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.